 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C5H7NO4S |
| Molar mass | 177.17 g·mol−1 |
| 3D model (JSmol) | |
| |
Cimlanod (development codesCXL-1427 andBMS-986231) is an experimental drug for the treatment ofacute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired byBristol-Myers Squibb. It is aprecursor ofnitroxyl.[1]
Cimlanod is aprodrug of CXL-1020.[2]
A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]
Alternative Names: BMS-986231; CXL 1427; HNO Donor
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
